Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures

Invasive Mycoses

Last Updated: November 10, 2016; Last Reviewed: November 10, 2016

Invasive Mycoses: Cryptococcosis, Histoplasmosis, Coccidioidomycosis
Member Financial Disclosure
Company Relationship
Ampel, Neil* University of Arizona Nielsen BioSciences Research Support
Blair, Janis Mayo Clinic Arizona None N/A
Hage, Chadi Indiana University None N/A
Hamill, Richard Baylor College of Medicine None N/A
Kauffman, Carol University of Michigan and VA Ann Arbor Healthcare System None N/A
Pappas, Peter University of Alabama at Birmingham Astellas Advisory Board, Consulting, Honoraria, Research Support
Merck Advisory Board, Research Support, Speaker’s Bureau
Pfizer Advisory Board, Research Support
T-2 Diagnostics Advisory Board
Perfect, John Duke University Amplyx Consultant, Research Support
Advisory Board, Consultant, Honoraria, Research Support
Cidara Consultant
F2G Consultant
Merck Advisory Board, Consultant, Honoraria, Research Support
Minnetronix Consultant, Research Support
Pfizer Consultant, Honoraria, Research Support
Scynexis Consultant
TEVA Honoraria
Viamet Consultant
Vical Consultant

* Group lead

Note: Members were asked to disclose all relationships from 24 months before the writing panel convened. The period of reporting was from November 1, 2014, through November 1, 2016.

Download Guidelines